

associated with cocaine use, but unlike the case described here, rhabdomyolysis tends to be associated with hypertension and malignant nephrosclerosis. While our patient did use cocaine, this is unlikely to be the root of the problem<sup>7</sup> given that the patient was originally hypotensive and experienced early renal function recovery.

While gabapentin levels were not measured, the rapid resolution of the delirium and recovery of renal function after only two sessions of low cut-off haemodialysis seem to indicate that gabapentin caused the symptoms. In fact, gabapentin is eliminated through renal excretion only, and since it does not bind to proteins, a single dialysis session will eliminate nearly 35% of the total.<sup>8,9</sup> In our case, this would explain the rapid improvement in symptoms. As in the other 2 cases of gabapentin-induced acute renal failure and rhabdomyolysis, the patients involved had multiple illnesses and were affected by multiple medications or other factors that might lead to rhabdomyolysis and renal failure. Another similarity was the rapid resolution of the condition and the improvement in Ck values after discontinuing the drug.

In summary, we can conclude that although it happens infrequently, gabapentin may cause myotoxicity, rhabdomyolysis and renal failure even in patients whose renal function was previously normal. This is why we must take special care with its dosage, with concomitant medications and the patient's co-morbidities, and why, after prescribing gabapentin, we must be watchful for any signs of muscle toxicity or kidney failure and quickly discontinue the drug if necessary.

#### Conflicts of interest

The authors declare they have no potential conflicts of interest related to the contents of this article.

1. Bilgir O, Calan M, Bilgir F, Kebapçılar L, Yüksel A, Yıldız Y, et al. Gabapentin-

induced rhabdomyolysis in a patient with diabetic neuropathy. *Intern Med* 2009;48(12):1085-7.

2. Bassilios N, Launay-Vacher V, Khoury N, Rondeau E, Deray G, Sraer JD. Gabapentin neurotoxicity in a chronic haemodialysis patient. *Nephrol Dial Transplant* 2001;16(10):2112-3.
3. Tuccori M, Lombardo G, Lapi F, Vannacci A, Blandizzi C, Del Tacca M. Gabapentin-induced severe myopathy. *Ann Pharmacother* 2007;41(7):1301-5.
4. Lipson J, Lavoie S, Zimmerman D. Gabapentin-induced myopathy in 2 patients on short daily hemodialysis. *Am J Kidney Dis* 2005;45(6):e100-4.
5. Guis S, Mattei JP, Cozzone PJ, Bendahan D. Pathophysiology and clinical presentations of rhabdomyolysis. *Joint Bone Spine* 2005;72: 382-91.
6. Marinella MA. Rhabdomyolysis associated with haloperidol without evidence of NMS. *Ann Pharmacother* 1997;31:927-8.
7. Horowitz BZ, Panacek EA, Jouriles NJ. Severe rhabdomyolysis with renal failure after intranasal cocaine use. *J Emerg Med* 1997;15(6):833-7.
8. Bluma RA, Pharm D, Thomas J, Schultz RW, Keller E, Reetze P, et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. *Clin Pharmacol Ther* 1994;56:154-9.
9. Wong MO, Eldon MA, Keane WF, Türck D, Bockbrader HN, Underwood BA, et al. Disposition of gabapentin in anuric subjects on hemodialysis. *J Clin Pharmacol* 1995;35(6):622-6.
10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther* 1981;30:239-45.

**Eduardo Torregrosa-de Juan, Pau Olagüe-Díaz, Pilar Royo-Maicas, Enrique Fernández-Nájera, Rafael García-Maset**

Sección de Nefrología.  
Hospital de Manises. Manises, Valencia.  
Spain.

**Correspondence:** Eduardo Torregrosa de Juan  
Sección de Nefrología.  
Hospital de Manises, Av. Generalitat Valenciana, 50, 46940 Manises. Valencia.  
Spain.  
torregrosa\_edu@gva.es  
etorregrosa@hospitalmanises.es

## Haemorrhagic fever with renal failure syndrome: a case report

*Nefrologia* 2012;32(1):131-2

doi:10.3265/Nefrologia.pre2011.Dec.11225

#### To the Editor,

Haemorrhagic fever with renal syndrome (HFRS) is a clinical condition secondary to infection with a hantavirus (Hantaan, Seoul, No Name, Andes virus, Puumala and Dobrava); the latter two varieties are endemic in rural areas of Eastern Europe, and of the two, infection with the Puumala virus has a better long-term prognosis.<sup>1</sup>

Rodents are the natural carriers of hantavirus, which is transmitted to humans when they come into direct contact with rodent secretions (urine, faeces and saliva).

The natural evolution of the disease entails 4 successive phases following an incubation period of about 3 weeks. The first phase is characterised by fever, followed by a phase with shock and oliguria; patients who survive this phase enter a phase with polyuria, which in turn is followed by a convalescence period of variable duration.

Thrombocytopenia is common and may produce haemorrhages at any location.

Renal symptoms include proteinuria, haematuria and decreased glomerular filtration rate. Direct vascular endothelial lesions and tubulo-interstitial nephritis mediated by cytokines have been proposed as the underlying pathophysiological cause.<sup>2</sup>

Diagnosis is based on a strong clinical suspicion, and confirmed by specific serological methods.<sup>3</sup> Kidney biopsy is not necessary.<sup>4</sup> A renal ultrasound can show the increase in kidney size and in resistance indices. Perirenal fluid collection is also a common finding (in addition to pleural or pericardial effusion or ascites). No vaccine or specific treatment exists; supportive therapy is of vital importance. One double-blind study showed decreased mortality given early treatment with ribavirin.<sup>5</sup>


Below, we describe our hospital's experience with a case of HFRS secondary to infection with the Puumala virus.

The patient was a male aged 18 years with no relevant prior history who came to the Emergency Department due to fever, muscle aches and a frontal headache evolving over 3 days with no improvement following his doctor's prescription of amoxicillin-clavulanic acid and paracetamol. Two weeks before, he had been hiking in a rural area of Slovenia.

The physical examination found a fever of 39.2°C, normal blood pressure, no adenopathy, and diffuse pain upon abdominal palpation. The Emergency Department laboratory blood test found 10 010 leukocytes/mm<sup>3</sup> with no eosinophilia; thrombocytopenia of 32 000/mm<sup>3</sup> with no platelet additives; haemoglobin: 18; haematocrit: 48%; creatinine: 1.35mg/dl; urea: 47mg/dl; lactate dehydrogenase (LDH): 324U/l. All other blood tests were normal.

Microhaematuria was present.

Thoracic and abdominal radiographies were normal. The abdominal ultrasound and the abdominal and pelvic CT showed



**Figure 1.** Abdominal and pelvic computed tomography

morphologically normal kidneys with no ureteral dilation, with perirenal and pelvic free liquid. (Figure 1)

The patient was admitted for observation, which is why he was initially given empirical antibiotic treatment with ceftriaxone and levofloxacin after the samples were extracted. The day after admission, he suffered a conjunctival haemorrhage (Figure 2), tendency toward oliguria, the appearance of oedemas, and decreased renal function; his creatinine level was 2.7mg/dl. As a hantavirus infection was suspected, we opted for antiviral treatment with ribavirin (500mg/i.v. every 8 hours). The same day, 8 hours later, he suffered an episode of dyspnoea and tachypnoea with desaturation (89%) and hypoxia (pO<sub>2</sub>: 63), and the decision was made to send him to the Intensive Care Unit. On the fourth day after admission, the patient presented epistaxis that subsided with anterior nasal packing. The oliguria became more pronounced, oedemas increased and the renal function worsened with creatinine levels of 5.6mg/dl. We then decided to start haemodialysis by means of a temporary catheter in the right femoral vein. After 4 session of haemodialysis, we observed improvements in urinary volume and renal function. The immunological study (antinuclear antibodies, anti-neutrophil cytoplasmic antibodies, anti-DNA, anti-GBM antibodies, complementary components, immunoglobulins, protein electrophoresis, cryoglobulin, circulating immune complexes) and serology study for hepatitis B and C, HIV, Epstein-Barr virus, cytomegalovirus, leptospira, parvovirus B19 and toxoplasma were negative or normal. On day 7, the laboratory reported IgG (+) 1/512 for Puumala



**Figure 2.** Conjunctival haemorrhage appearing the day after patient was admitted

virus, and antibiotic treatment was consequently discontinued.

On day 13, the patient was discharged after completing the antiviral treatment, showing recovered renal function and a creatinine level of 1.25. At follow-up 5 weeks later, his renal function was completely normal (creatinine: 0.69, estimated glomerular filtration rate >60).

### Conflicts of interest

The authors declare they have no potential conflicts of interest related to the contents of this article.

1. Miettinen MH, Mäkelä SM, Ala-Houhala IO, Huhtala HS, Kööbi T, Vaheri AI, et al. Ten-year prognosis of Puumala hantavirus-induced acute interstitial nephritis. *Kidney int* 2006;69:2043-8.
2. Mäkelä S, Mustonen J, Ala-Houhala I, Hurme M, Koivisto AM, Vaheri A, et al. Urinary excretion of interleukin-6 correlates with proteinuria in acute Puumala hantavirus-induced nephritis. *Am J Kidney Dis* 2004;43:809-16.
3. Vapalahti O, Mustonen J, Lundkvist A, Henttonen H, Plyusnin A, Vaheri A. Hantavirus infections in Europe. *Lancet Infect Dis* 2003;3:653-61.
4. Kim S, Sung SH, An HR, Jun YH, Yu M, Ryu DR, et al. A case report of crescentic glomerulonephritis associated with hantavirus infection. *Nephrol Dial Transplant* 2010;25(8):2790-2.
5. Huggins JW, Hsiang CM, Cosgriff M, Guang MY, Smith JI, Wu ZO, et al. Prospective, double-blind, concurrent, placebo-controlled clinic trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. *J Infect Dis* 1991;164:1119-27.

### Rodrigo Avellaneda-Campos

Unidad de Nefrología.  
Hospital Universitario Donostia.  
San Sebastián, Gipuzkoa. Spain.

### Correspondence:

Rodrigo Avellaneda Campos  
Unidad de Nefrología.  
Hospital Universitario Donostia.  
San Sebastián, Gipuzkoa. Spain.  
herlessrodrigo.avellanedacampos@osakidetza.net